Jefferies Financial Group Inc. Purchases New Shares in Replimune Group, Inc. $REPL

Jefferies Financial Group Inc. purchased a new position in Replimune Group, Inc. (NASDAQ:REPL) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 495,465 shares of the company’s stock, valued at approximately $5,485,000. Jefferies Financial Group Inc. owned approximately 0.59% of Replimune Group as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently added to or reduced their stakes in REPL. Quantinno Capital Management LP increased its holdings in shares of Replimune Group by 782.7% in the first quarter. Quantinno Capital Management LP now owns 108,477 shares of the company’s stock worth $830,000 after buying an additional 96,188 shares during the period. EcoR1 Capital LLC purchased a new stake in Replimune Group during the 1st quarter valued at about $7,650,000. Seven Fleet Capital Management LP bought a new position in Replimune Group during the 1st quarter worth approximately $921,000. Candriam S.C.A. bought a new position in Replimune Group during the 1st quarter worth approximately $3,014,000. Finally, Persistent Asset Partners Ltd purchased a new position in Replimune Group in the 4th quarter worth approximately $598,000. 92.53% of the stock is currently owned by institutional investors and hedge funds.

Replimune Group Trading Down 0.6%

NASDAQ REPL opened at $15.50 on Friday. Replimune Group, Inc. has a fifty-two week low of $1.50 and a fifty-two week high of $16.15. The company has a debt-to-equity ratio of 1.00, a quick ratio of 5.23 and a current ratio of 5.23. The stock has a 50 day simple moving average of $11.84 and a two-hundred day simple moving average of $8.34. The stock has a market cap of $1.45 billion, a P/E ratio of -4.92 and a beta of 0.88.

Replimune Group (NASDAQ:REPL) last posted its earnings results on Friday, August 14th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.69) by ($0.03). On average, analysts forecast that Replimune Group, Inc. will post -2.94 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts have weighed in on REPL shares. Piper Sandler upgraded Replimune Group from a “hold” rating to a “strong-buy” rating in a research report on Friday, July 31st. Wall Street Zen upgraded shares of Replimune Group from a “strong sell” rating to a “sell” rating in a report on Saturday, May 23rd. Weiss Ratings downgraded shares of Replimune Group from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, August 11th. BMO Capital Markets upgraded shares of Replimune Group from an “underperform” rating to an “outperform” rating and set a $16.00 price target for the company in a report on Tuesday, June 30th. Finally, JPMorgan Chase & Co. raised their price target on shares of Replimune Group from $20.00 to $21.00 and gave the stock an “overweight” rating in a report on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $12.00.

Insiders Place Their Bets

In other news, CFO Emily Luisa Hill sold 9,256 shares of the firm’s stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $14.28, for a total value of $132,175.68. Following the completion of the sale, the chief financial officer directly owned 215,852 shares of the company’s stock, valued at approximately $3,082,366.56. This trade represents a 4.11% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Konstantinos Xynos sold 11,447 shares of Replimune Group stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $12.97, for a total transaction of $148,467.59. Following the sale, the insider directly owned 224,215 shares in the company, valued at $2,908,068.55. The trade was a 4.86% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 91,124 shares of company stock valued at $1,149,244 over the last quarter. 5.40% of the stock is owned by company insiders.

Replimune Group Company Profile

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.